11.31USD+0.58%Mkt Cap: 3.55B USDP/E: —Last update: 2026-05-26
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap3.55B USD
Enterprise Value3.41B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-124.55M USD
Revenue/Share—
Last Price11.31 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees103
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-20.58
PEG—
EV/EBITDA-26.10
EV/Revenue—
P/S—
P/B9.17
EPS (TTM)-0.93
EPS (Forward)-0.56
52W Range
1.06044% of range24.28
52W High24.28 USD
52W Low1.060 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-38.30%
ROA-31.44%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-95.45M USD
CapEx (TTM)9.63M USD
FCF Margin—
FCF Yield-6.00%
Net Debt-197.84M USD
Net Debt/EBITDA1.51
Balance Sheet
Debt/Equity0.14
Current Ratio9.52
Quick Ratio9.27
Book Value/Sh1.266 USD
Cash/Share0.7840 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)20.30 USD
Target Range9.000 USD – 30.00 USD
# Analysts10
Ownership
Shares Out.310.98M
Float207.89M
Insiders10.66%
Institutions92.96%
Short Interest
Short Ratio3.4d
Short % Float11.56%
Short % Out.10.31%
Shares Short32.06M
Short (prev mo.)29.89M
Technical
SMA 5014.59 (-22.5%)
SMA 2007.449 (+51.8%)
Beta0.68
S&P 52W Chg28.31%
Avg Vol (30d)7.88M
Avg Vol (10d)3.82M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—